BioTuesdays

Tag - VTGN

Vistagen Logo

Vistagen presents Phase 3 data for SAD

Vistagen (NASDAQ:VTGN) presented positive safety and exploratory efficacy data at the American Society for Clinical Psychopharmacology annual meeting in Miami from its large Phase 3 open-label study of fasedienol nasal...